US EditionIgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
- Novartis announced FDA's accelerated approval of Vanrafia for IgAN on April 2, 2025.
- IgAN patients with rapid progression risk now have a new treatment option to reduce proteinuria.
- Phase III data showed a 36.1% proteinuria reduction with Vanrafia versus placebo .
- Richard Lafayette stated Vanrafia offers IgAN patients a new treatment option without a REMS requirement.
- Vanrafia's approval expands IgAN treatment, though responses can vary among patients.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
All
Left
2
Center
7
Right
3
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsIgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
(MedPage Today) -- The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday. The tablets are indicated...
·New York, United States
Read Full Article
Rutland Herald+26 Reposted by 26 other sources
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P
Coverage Details
Total News Sources36
Leaning Left2Leaning Right3Center7Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 17%
C 58%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
